Comparison of the Immunogenicity and Reactogenicity of Cervarix and Gardasil Human Papillomavirus Vaccines in HIV-Infected Adults: A Randomized, Double-Blind Clinical Trial

Abstract

Both vaccines were immunogenic and well tolerated. Compared with Gardasil, Cervarix induced superior vaccine responses among HIV-infected women, whereas in HIV-infected men the difference in immunogenicity was less pronounced.

Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives

“…36 None of the vaccines negatively affected CD4 + cell counts or HIV RNA levels. Injection site reactions were more common in the bivalent compared with the quadrivalent vaccine group, but both vaccines were generally well tolerated.…”

“…Sex-specific seroconversion rates were not evaluated in the study but women immunised by either of the HPV vaccines had high antibody titres against HPV-16 and -18. 36 The efficacy of the quadrivalent HPV vaccine was previously investigated in healthy adult women in a randomised, placebo-controlled, double-blinded trial, 44 where 3819 women aged 24-45 years with no history of cervical disease or genital warts in the past 5 years before inclusion were enrolled in a study with a mean follow-up period of 4 years. Vaccine efficacy was 47.2% (95% confidence interval (CI): 33.5-58.2) against a combined endpoint: incidence of persistent infection (!6 months' duration), cervical intraepithelial neoplasia or external genital lesions related to HPV-6, -11, -16 and -18.…”

“…Solid antibody responses following HPV vaccination were observed in the two trials that included male HIV-positive adults. 35,36 Vaccine efficacy has been established against persistent anal HPV-16 and -18 infection among 602 HIV-negative MSM aged 16-26 years. 21 During a follow-up with a median of 2.9 years, vaccine efficacy was 57.5% (95% CI: 33.2-73.6) against persistent anal infection with HPV-16 and -18 and 55.2% (95% CI: 8.5-79.3) against anal intraepithelial neoplasia related to HPV-16 and -18.…”

Comparison of the immunogenicity of Cervarix®and Gardasil®human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults

“…A limited number of studies have demonstrated immunogenicity of Gardasil ®23-26 and Cervarix ®27 in HIV-infected populations and one study has compared the immunogenicity of the 2 vaccines. 28 Recently, it has been demonstrated that Gardasil ® induces HPV-31 cross-neutralizing antibodies in HIV-infected children. 29 The potential induction of HPV-33 and -45 cross-neutralizing antibodies from Gardasil ® and Cervarix ® vaccination has never been investigated in HIV-infected individuals.…”

“…28 This study presents data on cross-reactive serological neutralizing antibody responses against HPV-31, -33, and HPV-45 for Cervarix ® and Gardasil ® in an HIV-infected adult population.…”